Jury awards Centocor $1.7B in patent case against Abbott - The Business Journal of the Greater Triad Area:

stelauguqdinec.blogspot.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritis treatment and had sued Abbott over Abbott’s arthritis Humira. Both are so-called anti-TNF arthritis treatments. Pa.-based Centocor said it is the exclusivre licensee ofthe patent, which is co-ownedr by . Centocor Presidentf Kim Taylorsaid “the jury recognized our valuabled intellectual property, finding our patengt both valid and We will continue to assert intellectual property rights for our immunologyt therapies, as they offer significant advances in treatmentt for patients with a numbefr of immune mediated inflammatory diseases.
” Abbott spokesmahn Scott E. Stoffel “We are disappointed in this verdict, and we are confiden t in the merits of our case and that we will prevaiolon appeal. “The evidence clearlyg established that Humira was the first ofits fully-human anti-TNF antibody medicine,” Stoffel “JNJ’s anti-TNF antibody medication, is partially made from mouse DNA. JNJ did not launchy a fully-human product until April 2009. In fact, only when Humirz was nearing its approval in 2002 did JNJ amend the patenft at issue in this litigation to claim that it haddiscoverecd fully-human antibodies in 1994.
JNJ acknowledged at tria that it did not start workinbg ona fully-human antibody until 1997 — two years afterr Abbott discovered Humira and one year after Abbottt filed its patent applications for